NCT07119450已完成1 期
A Mass Balance Study of [14C] GZR18 in Chinese Overweight or Obese Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Primary Outcome Measure
研究概览
简要总结
This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study.
The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine collection period (D1 to D36) and an intermittent collection and follow-up period (D36 to D78, during which subjects should visit the hospital once a week, 6 visits in total).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects must be fully informed, know and understand the content, process and possible treatment-related adverse events (TRAEs) before the study, and voluntarily sign a written informed consent form;
- •Chinese adult male subjects aged 18-55 (inclusive);
- •Body weight ≥ 50 kg;
- •Subjects with stable physical activity and lifestyle and relatively stable weight within 3 months prior to screening (as per inquiry);
- •Subjects have no sperm donation plan within 6 months after the last dose, and subjects and their partners have no pregnancy plan throughout the study and within 6 months after the last dose and voluntarily take effective contraceptive measures to avoid pregnancy of their partners.
排除标准
- •Subjects with other clinically significant diseases or medical history that may hinder the subject from following the study protocol and completing this study as judged by the investigator.
- •Subjects with abnormalities in vital signs, physical examination, routine laboratory tests (hematology, urinalysis, stool analysis + occult blood, blood chemistry and coagulation function), chest X-ray (AP view) or abdominal B-scan ultrasonography at screening or baseline, which are deemed clinically significant by the investigator; subjects with alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin exceeding the normal range at screening/baseline, which are deemed clinically significant by the investigator.
- •Subjects who suffer from dyspepsia, esophageal reflux, peptic ulcer or gallbladder disease within 3 months prior to dosing, or any gastrointestinal disease that may affect gastric emptying, or any surgical procedure (such as cholecystectomy, except for appendicitis surgery) that may affect drug metabolism or excretion; or plan to undergo surgery during the study.
- •Subjects who used any prescription drugs, OTC drugs, Chinese herbal medicines, food supplements (including vitamins, health food, etc.) within 14 days before dosing, or have other non-drug therapeutic factors affecting drug absorption, distribution, metabolism and excretion.
- •ubjects who have received any other investigational drug or participated in any other interventional clinical study within 3 months prior to screening, or still within 5 half-lives of a previously administered investigational drug at screening, whichever is longer.
- •Difficulty in blood collection or intolerance to venipuncture for blood collection.
- •Subjects who smoked > 5 cigarettes/day on average (or used an equivalent amount of nicotine products) in 6 months prior to screening, or are unwilling to abstain from tobacco products during the study.
- •Those who are not eligible for the study for other reasons as judged by the investigator.
研究组 & 干预措施
GZR18 injection、[14C]GZR18 injection
Experimental
干预措施: GZR18 injection、[14C]GZR18 injection (Drug)
结局指标
主要结局
Primary Outcome Measure
时间窗: Through study completion, an average of 1 year
Half-Life Period（T1/2）
次要结局
- PK parameters of GZR18 and its metabolites (if applicable) in plasma(through study completion, an average of 1 year)
- Safety Evaluation:Clinical safety evaluation during the study(Average of 1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Mass Balance Study of [14C]JT001Healthy SubjectsNCT05802810Shanghai Vinnerna Biosciences Co., Ltd.7
已完成
1 期
Mass Balance Study of [14C]X842 in Healthy Adult Male SubjectsNCT07107672Jiangsu Sinorda Biomedicine Co., Ltd6
已完成
1 期
The Mass Balance Study of LP-168 in Healthy SubjectsClinical PharmacologyNCT06126861Guangzhou Lupeng Pharmaceutical Company LTD.6
已完成
1 期
Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male SubjectsHealthyNCT04654897Bayer6
已完成
1 期
Mass Balance Study of [14C]-Orvepitant Oral Solution in Healthy Male SubjectsHealthyNCT04387981Nerre Therapeutics Ltd.6